

		Intervention:	Biological: Cervarix™ (GSK580299)
1056	Recruiting	A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract	
		Condition:	Head and Neck Squamous Cell Carcinoma
		Interventions:	Drug: Tadalafil; Drug: Placebo
1057	Active, not recruiting	Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-	
		Condition:	Melanoma
		Intervention:	Biological: Autologous, lethally irradiated melanoma cells
1058	Active, not recruiting	Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: sargramostim; Other: immunoenzyme technique; Other: immunohistochemistry staining method;
1059	Recruiting	Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease	
		Conditions:	Juvenile Idiopathic Arthritis; Systemic Lupus Erythematosus; Juvenile Dermatomyositis
		Intervention:	Drug: Human papilloma virus vaccine (cervarix)
1060	Completed Has	Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients	
		Condition:	Adult Stem Cell Hematopoetic Transplant
		Interventions:	Biological: High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV); Biological: Standard Dose Trivalent Inactivated Flu Vaccine
1061	Unknown †	The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in	
		Conditions:	Chronic Kidney Disease, Stage IV (Severe); Chronic Kidney Disease, Stage V
		Intervention:	Biological: HPV-6/11/16/18 vaccine
1062	Recruiting	Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells	
		Condition:	Melanoma
		Interventions:	Drug: Poly ICLC; Procedure: leukapheresis
1063	Not yet recruiting	Lipo peptide Immunisation With GTU-multiHIV Trial	
		Condition:	HIV-1 Infection
		Interventions:	Biological: Placebos of GTU-multiHIV B and LIPO-5 vaccines; Biological: GTU-multiHIV B vaccine and LIPO-5
1064	Completed	Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma	
		Condition:	Multiple Myeloma
		Intervention:	Biological: Therapeutic Cellular Vaccine, GM-CSF Producing
1065	Completed	Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer	
		Condition:	Head and Neck Cancer
		Interventions:	Biological: aldesleukin; Biological: recombinant interleukin-12; Biological: sargramostim; Other: immunologic technique; Procedure: biopsy
1066	Recruiting	A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic	
		Condition:	Prostate Cancer Metastatic
		Interventions:	Biological: PROSTVAC-V; Biological: PROSTVAC-F; Drug: GM-CSF; Other: GM-CSF Placebo; Biological: Placebo
1067	Completed	Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer	
		Condition:	Cancer

1068	Unknown †	Interventions:	Biological: EC90 (KLH-FITC); Biological: GPI-0100; Drug: EC17 (Folate-FITC); Drug: Interleukin-2; Drug: Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia
		Condition:	Leukemia
		Intervention:	Biological: recombinant 70-kD heat-shock protein
1069	Terminated	Intervention:	Dendritic Cell Based Therapy of Metastatic Breast Cancer
		Condition:	Metastatic Breast Cancer
		Intervention:	Biological: Onco-peptide loaded autologous dendritic cells
1070	Completed Has	Intervention:	Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy
		Condition:	Inflammatory Bowel Disease
		Intervention:	Biological: Gardasil vaccine
1071	Recruiting	Intervention:	Clinical Study of WT2725 in Patients With Advanced Solid Malignancies
		Condition:	Cancer
		Intervention:	Biological: WT2725
1072	Recruiting	Intervention:	A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
		Condition:	Colon Cancer
		Interventions:	Drug: chemotherapy and GI-4000; Drug: GI-4000
1073	Active, not recruiting	Intervention:	Prevention of HPV in 20 to 45 Year Old Chinese Women (V501-041 AM1 EXT1)
		Condition:	HPV Infections
		Interventions:	Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine; Biological:
1074	Active, not recruiting	Intervention:	A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
		Condition:	Glioblastoma Multiforme
		Interventions:	Biological: ICT-107; Biological: Placebo DC
1075	Recruiting	Intervention:	Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)
		Conditions:	Acute Lymphocytic Leukemia; Acute Myelogenous Leukemia; Burkitt's Lymphoma; Follicular Lymphoma; Hodgkin Lymphoma; Mantle Cell Lymphoma
		Interventions:	Drug: Biological/Vaccine: Haploidentical BMT; Drug: Double Cord Blood Transplantation
1076	Enrolling by invitation	Intervention:	Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females
		Condition:	Human Papillomavirus
		Interventions:	Biological: HPV 16/18 vaccine, 0,5ml; Biological: Placebo control, 0.5ml; Biological: HPV 16/18 vaccine, 1.0ml; Biological: Placebo control, 1.0ml
1077	Completed Has	Intervention:	A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females
		Conditions:	Human Papillomavirus (HPV) Infection; Papillomavirus Vaccines
		Intervention:	Biological: GSK580299 (Cervarix™, HPV -16/18 L1 VLP AS04 vaccine)
1078	Terminated	Intervention:	Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities
		Condition:	Cervical Cancer
		Intervention:	Behavioral: Academic Detailing
1079	Completed	Intervention:	Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma
		Condition:	Neuroblastoma
		Interventions:	Biological: gene-modified tumor cell vaccine therapy; Biological: interleukin-2 gene
1080	Recruiting	Intervention:	Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
		Condition:	Melanoma

		Interventions:	Biological: POL-103A; Biological: POL-103A without API
1081	Recruiting	Combination Therapy of Topical Imiquimod Plus Multi-peptide Vaccination for Cutaneous Metastases of Melanoma	
		Condition:	Melanoma
		Interventions:	Biological: MELITAC 12.1; Drug: Imiquimod
1082	Recruiting	Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer	
		Conditions:	Non-small Cell Lung Cancer; Progression of Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Recurrent
		Interventions:	Drug: Docetaxel; Biological: HyperAcute®-Lung Immunotherapy; Drug: Gemcitabine; Drug: Pemetrexed
1083	Recruiting	Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer	
		Conditions:	Pancreatic Cancer; Pancreatic Carcinoma Non-resectable; Locally Advanced Malignant Neoplasm
		Interventions:	Drug: FOLFIRINOX; Biological: HyperAcute®-Pancreas Immunotherapy; Radiation: 5-FU Chemoradiation;
1084	Recruiting	Immunotherapy Study for Surgically Resected Pancreatic Cancer	
		Condition:	Pancreatic Cancer
		Interventions:	Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
1085	Completed	Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil	
	Has	Condition:	Dose Schedule Study
		Intervention:	Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
1086	Not yet recruiting	Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma	
		Condition:	Multiple Myeloma
		Interventions:	Biological: aMILS; Drug: no aMILS
1087	Completed	Phase II Trial of Allovectin-7® for Metastatic Melanoma	
		Conditions:	Melanoma; Metastatic Melanoma; Malignant Melanoma; Skin Cancer
		Intervention:	Genetic: Allovectin-7®
1088	Unknown †	Safety and Pharmacodynamic Study of a New Formulation, AGI – 101H Vaccine in the Treatment of Advanced Melanoma	
		Condition:	Melanoma
		Intervention:	Biological: AGI-101H Vaccine
1089	Recruiting	Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression	
		Condition:	Immunosuppression
		Intervention:	Biological: Flu Vaccine
1090	Completed	A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the	
		Condition:	Prostatic Neoplasms
		Intervention:	Biological: PROSTVAC
1091	Not yet recruiting	Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission	
		Condition:	Acute Myeloid Leukemia
		Intervention:	Biological: DC vaccine
1092	Recruiting	Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro	
		Condition:	Multiple Myeloma
		Intervention:	Procedure: Blood draws

1093	Completed Has	Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults	
		Conditions:	Influenza A Virus, H1N1 Subtype; Influenza Infection
1094	Completed	Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells	
		Condition:	Multiple Myeloma
		Intervention:	Biological: Idiotype-pulsed allogeneic dendritic cells
1095	Completed	Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma	
		Condition:	Melanoma (Skin)
1096	Completed	Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma	
		Condition:	Malignant Melanoma
		Intervention:	Biological: GV1001
1097	Active, not recruiting	Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients	
		Condition:	Melanoma
1098	Unknown †	The Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2	
		Condition:	Metastatic Melanoma
		Intervention:	Procedure: Immunotherapy treatment for melanoma
1099	Completed	Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients	
		Condition:	Malignant Melanoma
		Interventions:	Biological: CYT004-MelQbG10 + Montanide; Biological: CYT004-MelQbG10 + Montanide + Imiquimod;
1100	Active, not recruiting	Safety of Active Immunotherapy in Subjects With Ovarian Cancer	
		Condition:	Ovarian Epithelial Cancer
1101	Recruiting	Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma	
		Condition:	Metastatic Melanoma
		Interventions:	Drug: Ipilimumab; Other: Radiation Therapy and Ipilimumab
1102	Active, not recruiting	Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection	
		Condition:	Glioblastoma Multiforme
1103	Completed	Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma	
		Condition:	Influenza
		Intervention:	Biological: Recombinant rHAO
1104	Completed	Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1)	
		Conditions:	Metastatic Breast Cancer; Recurrent Breast Cancer
1105	Completed	Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With	
		Conditions:	Acquired Immunodeficiency Syndrome; HIV Infection

1106	Completed	Interventions: Drug: PCLUS 3-18 MN; Drug: PCLUS 6.1 MN
		Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe)
		Condition: Metastatic Breast Cancer
1107	Completed	Intervention: Biological: AdHer-2/neu transduced dendritic cells
		Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants
		Condition: Nonneoplastic Condition
1108	Recruiting	Interventions: Biological: PADRE-CMV fusion peptide vaccine; Biological: tetanus-CMV fusion peptide vaccine; Drug:
		A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients
		Condition: Melanoma
1109	Recruiting	Interventions: Biological: MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS); Biological: MELITAC 12.1 + Montanide
		IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma
		Conditions: Malignant Melanoma Stage III; Malignant Melanoma Stage IV
1110	Completed	Intervention: Biological: IL15-DC Vaccine
		Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.
		Condition: Prophylaxis HPV Infection
1111	Enrolling by invitation	Intervention: Biological: HPV vaccine
		BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients
		Condition: Bladder Cancer
1112	Completed	Interventions: Biological: MAGE-A3 ASCI; Biological: BCG
		Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation
		Condition: Unspecified Adult Solid Tumor, Protocol Specific
1113	Completed	Interventions: Biological: aldesleukin; Biological: therapeutic autologous lymphocytes; Biological: therapeutic tumor infiltrating
		Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
		Conditions: HIV Infections; Sexually Transmitted Diseases
1114	Completed	Intervention: Biological: Quadrivalent human papillomavirus vaccine
		Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic
		Conditions: HIV Infections; Healthy
1115	Recruiting	Intervention:
		Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer
		Conditions: Stage II Breast Cancer; Stage III Breast Cancer
1116	Active, not recruiting	Intervention: Biological: Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens
		Vaccine Acceptance in Pregnant Minority Women
		Condition: Pregnancy
1117	Active, not recruiting	Intervention: Behavioral: Maternal Vaccine Education
		Activated White Blood Cells in Treating Patients Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Stage II or Stage III
		Condition: Multiple Myeloma and Plasma Cell Neoplasm
1118	Recruiting	Interventions: Biological: therapeutic autologous lymphocytes; Biological: therapeutic tumor infiltrating lymphocytes; Drug:
		A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRVIII-Positive Glioblastoma

		Conditions:	Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma
		Interventions:	Drug: Bevacizumab; Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: KLH
1119	Completed	Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of	
		Condition:	Human Papillomavirus (HPV)
		Intervention:	Biological: VGX-3100
1120	Completed	A Safety Trial of MVA-BN[®]-PRO in Men With Androgen-Insensitive Prostate Cancer	
		Condition:	Androgen-insensitive Prostate Cancer
		Intervention:	Biological: MVA-BN-PRO
1121	Completed	Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease	
	Has	Conditions:	Inflammatory Bowel Disease; Uterine Cervical Dysplasia
		Intervention:	Biological: Human Papillomavirus Vaccine
1122	Active, not recruiting	A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation	
		Conditions:	Acute Myelogenous Leukemia (AML); Chronic Myelogenous Leukemia (CML); Acute Lymphoblastic Leukemia (ALL); Myelodysplastic Syndrome (MDS); B Cell Malignancies
		Intervention:	Biological: WT1 derived peptides
1123	Completed	Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy	
		Conditions:	Neovascular Maculopathy; Age Related Macular Degeneration
		Intervention:	Biological: VEGFR1 and VEGFR2
1124	Active, not recruiting	HPV in Adolescents	
		Conditions:	HPV Infection; Cervical/Anal Dysplasia
		Intervention:	
1125	Completed	GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)	
		Condition:	Papillomavirus Infections
		Interventions:	Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™);
1126	Completed	V930 First in Man (FIM) Study	
		Condition:	Cancers Expressing HER-2 and/or CEA
		Intervention:	Biological: V930
1127	Terminated	Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies	
		Conditions:	Preleukemia; Myeloproliferative Disorders; Lymphoma; Myeloma; Graft Versus Host Disease
		Interventions:	Drug: Fludarabine; Drug: Melphalan; Drug: Campath
1128	Unknown †	Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients	
		Condition:	Ataxia Telangiectasia
		Interventions:	Biological: Prevenar® (7-valent pneumococcal conjugate vaccine); Biological: Pneumovax® (pneumococcal
1129	Recruiting	Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects	
		Conditions:	Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
		Intervention:	Procedure: Gynaecological follow-up
1130	Not yet recruiting	Modulation of Immune Response by Oral Zinc Supplementation in Chemotherapy for Colon Cancer	
		Conditions:	Adjuvant Chemotherapy; Colon Cancer; Immunity
		Interventions:	Dietary Supplement: zinc; Other: Placebo

1131	Terminated	PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer	
		Conditions:	Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
		Interventions:	Biological: PEG-interferon alfa-2b; Drug: PEG-interferon alfa-2b
1132	Recruiting	Plasmacytoid Dendritic Cell Vaccines in Metastatic Melanoma Patients	
		Condition:	Melanoma
		Intervention:	Biological: PDC
1133	Recruiting	Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer	
		Conditions:	Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer
		Interventions:	Biological: AdGMCAIX-transduced autologous dendritic cells; Biological: therapeutic autologous dendritic cells; Other: laboratory biomarker analysis
1134	Terminated	A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma	
		Condition:	Renal Cell Carcinoma
		Interventions:	Biological: EC90 (KLH-FITC); Biological: GPI-0100; Drug: EC17 (Folate-FITC); Drug: Interleukin-2; Drug:
1135	Active, not recruiting	A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)	
		Condition:	Acute Myelogenous Leukemia
		Intervention:	Biological: GRNVAC1
1136	Recruiting	Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT	
		Conditions:	Non-Hodgkin's Lymphoma; Leukemia; Multiple Myeloma; Acute Myeloid Leukemia; Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Myelodysplastic Syndrome
		Intervention:	Biological: thymoglobulin
1137	Recruiting	Study to Assess the Safety and Immunological Response of Stage IIIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI	
		Condition:	Melanoma
		Intervention:	Biological: recMAGE-A3 + AS15 ASCI
1138	Terminated	Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck	
		Conditions:	Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
		Intervention:	Biological: PV701
1139	Completed	Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young	
		Condition:	H1N1 Pandemic Flu
		Intervention:	
1140	Recruiting	A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas	
		Conditions:	Newly Diagnosed Pediatric Pontine Glioma.; Newly Diagnosed Pediatric High Grade Glioma.; Recurrent Pediatric High Grade Glioma.; Recurrent Pediatric Low Grade Glioma.

		Interventions:	Biological: HLA-A2 restricted synthetic glioma antigen peptides vaccine; Drug: Poly ICLC; Genetic: Reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
1141	Active, not recruiting Has	A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer (CLEOPATRA)	
		Condition:	Metastatic Breast Cancer
		Interventions:	Drug: Pertuzumab; Drug: Placebo; Drug: Trastuzumab; Drug: Docetaxel
1142	Recruiting	Anti-TNF Agents for the Treatment of Rheumatoid Arthritis	
		Condition:	Rheumatoid Arthritis
		Interventions:	Drug: Etanercept; Drug: Adalimumab
1143	Recruiting	Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes	
		Condition:	Non Small Cell Lung Cancer
		Intervention:	Biological: Dex2
1144	Recruiting	Pilot Immunotherapy Trial for Recurrent Malignant Gliomas	
		Condition:	Malignant Glioma of Brain
		Interventions:	Drug: IGF-1R/AS ODN; Device: biodiffusion chamber
1145	Completed	Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation	
		Condition:	Smoking
		Interventions:	Biological: TA-NIC; Biological: Placebo
1146	Terminated	Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL	
		Conditions:	Chronic Lymphocytic Leukemia; Small Lymphocytic Leukemia
		Interventions:	Drug: Lenalidomide; Drug: Fludarabine; Drug: Rituximab
1147	Completed	Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV	
		Condition:	Nonneoplastic Condition
		Interventions:	Biological: E1M184V peptide vaccine; Biological: incomplete Freund's adjuvant; Biological: sargramostim;
1148	Recruiting	Investigation of the Influence of Gender on Cardiovascular Function	
		Condition:	Cardiovascular Function
		Intervention:	Biological: Typhoid vaccine
1149	Completed	Effect of Tai Chi Vs. Structured Exercise on Physical Fitness and Stress in Cancer Survivors	
		Conditions:	Cancer; Cancer Survivor
		Intervention:	Procedure: Tai Chi Chuan
1150	Recruiting	Collection and Distribution of Blood Samples From Healthy Donors for In Vitro Research at the NCI Frederick Cancer Research and	
		Condition:	Samples
		Intervention:	
1151	Completed	Hepatitis A Vaccine in Patients With Immunomodulating Drugs	
		Condition:	Response to Hepatitis A Vaccine
		Intervention:	Biological: hepatitis A vaccine (HAVRIX or EPAXAL)
1152	Completed	Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease	
		Conditions:	Inflammatory Bowel Disease; Crohn Disease; Ulcerative Colitis
		Intervention:	Biological: 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
1153	Recruiting	Three Doses of Hepatitis A Vaccine in Patients With Immunomodulating Drugs	
		Condition:	Vaccine Response Impaired

		Intervention:	Biological: hepatitis A vaccine
1154	Completed	Vaccination With Tumor mRNA in Metastatic Melanoma – Fixed Combination Versus Individual Selection of Targeted Antigens	
		Condition:	Malignant Melanoma
		Interventions:	Biological: mRNA coding for melanoma associated antigens; Drug: GM-CSF
1155	Recruiting	Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma	
		Conditions:	Recurrent Malignant Mesothelioma; Stage IA Malignant Mesothelioma; Stage IB Malignant Mesothelioma; Stage II Malignant Mesothelioma; Stage III Malignant Mesothelioma; Stage IV Malignant Mesothelioma
		Interventions:	Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter; Other: laboratory biomarker analysis; Procedure: single photon emission computed tomography; Procedure: computed tomography
1156	Completed	Safety and Tolerability of the Derma Vax(Trademark) Clinical Intradermal Electroporation System in Healthy Subjects	
		Condition:	Intradermal Electroporation
		Interventions:	Drug: EMLA Cream; Drug: Aveeno Daily Moist; Device: Derma Vax; Procedure: Intradermal Electroporation; Procedure: Visual Analogue Scale; Procedure: Present Pain Intensity; Procedure: McGill Pain Questionnaire;
1157	Recruiting	Effects of Sulforaphane (SFN) on Immune Response to Live Attenuated Influenza Virus in Smokers and Nonsmokers	
		Condition:	Smoking
		Interventions:	Dietary Supplement: Broccoli sprout homogenate; Dietary Supplement: Alfalfa sprout homogenate
1158	Active, not recruiting	Viral Therapy in Treating Patients With Metastatic Melanoma	
		Conditions:	Recurrent Melanoma; Stage IV Melanoma
		Interventions:	Biological: wild-type reovirus; Other: laboratory biomarker analysis
1159	Completed	Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults	
		Condition:	Pneumococcal Disease
		Interventions:	Biological: PhtD vaccine with/without adjuvant; Biological: Pneumovax 23TM; Biological: NaCl
1160	Completed	A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus	
		Condition:	HIV Infections
		Intervention:	
1161	Terminated Has	Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer	
		Condition:	Prostate Cancer
		Interventions:	Drug: Docetaxel; Biological: CG1940/CG8711
1162	Completed	Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults	
		Condition:	HIV Infections
		Interventions:	Biological: DNA Vaccine; Biological: Placebo; Biological: rMVA vaccine
1163	Completed	Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine	
		Condition:	Cytomegalovirus
		Intervention:	Procedure: Blood sampling
1164	Recruiting	Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer	
		Condition:	Colorectal Cancer

		Interventions:	Biological: Imprime PGG + cetuximab; Drug: Cetuximab
1165	Completed	Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults	
		Condition:	Influenza
		Intervention:	Biological: Influenza Vaccine GSK1562902A - 6 different formulations
1166	Unknown †	Efficacy Study of TKcell in Advanced Colorectal Cancer	
		Condition:	Advanced Colorectal Cancer
		Intervention:	Biological: TKCell
1167	Completed	Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults	
	Has	Condition:	Influenza
		Interventions:	Biological: GSK Biologicals' FluLaval®; Biological: Placebo (saline); Biological: GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A; Biological: GSK Biologicals' investigational H1N1 Influenza Vaccine -
1168	Completed	Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma	
		Condition:	Malignant Mesothelioma
		Interventions:	Biological: recombinant interferon alfa; Drug: cisplatin; Procedure: surgical procedure; Radiation: radiation
1169	Active, not recruiting	Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients	
		Condition:	Melanoma
		Intervention:	Biological: autologous dendritic cell vaccination
1170	Recruiting	Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi's	
		Condition:	Sarcoma, Kaposi
		Interventions:	Drug: Liposomal Doxorubicin; Drug: Bevacizumab
1171	Recruiting	ZOSTAVAX® in Renal Transplant Patients	
		Condition:	Herpes Zoster
		Interventions:	Drug: Placebo; Biological: ZOSTAVAX® (Zoster Vaccine Live)
1172	Terminated	Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer	
		Condition:	Prostatic Neoplasms
		Interventions:	Biological: MVA 5T4; Drug: Docetaxel
1173	Unknown †	Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)	
		Condition:	Esophageal Cancer
		Intervention:	Biological: vaccination
1174	Unknown †	Active Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA	
		Condition:	Renal Cell Carcinoma
		Intervention:	Biological: DC RCC-RNA
1175	Unknown †	Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast	
		Condition:	Breast Cancer
		Intervention:	Biological: Dendritic Cell Vaccination
1176	Recruiting	Host Dendritic Cells in Allograft Patients	
		Conditions:	Relapsed Non-Hodgkin's Lymphoma; Hodgkin's Disease; Multiple Myeloma; Chronic Lymphocytic Lymphoma